...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Ophthalmology >A prospective randomized controlled study of Aurolab aqueous drainage implant versus Ahmed glaucoma valve in refractory glaucoma: A pilot study
【24h】

A prospective randomized controlled study of Aurolab aqueous drainage implant versus Ahmed glaucoma valve in refractory glaucoma: A pilot study

机译：Aurolab水性引流植入物与Ahmed青光眼瓣膜治疗难治性青光眼的前瞻性随机对照研究

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To study the efficacy of the Aurolab aqueous drainage implant (AADI) compared to Ahmed glaucoma valve (AGV) in patients with refractory glaucoma. Methods:18 years) scheduled for a glaucoma drainage device (GDD) were randomized into two groups to receive either AGV or AADI. Primary outcome measures: intraocular pressure (IOP) control and requirement of antiglaucoma medications; secondary outcome measures: final best correct visual acuity (log MAR), visual field (Visual field index [VFI], mean deviation [MD] and pattern standard deviation [PSD]), postoperative complications and additional interventions. Complete success was defined as IOP ≥5–≤18 mmHg without antiglaucoma medications/laser/additional glaucoma surgery or any vision threatening complications. Results: There were 19 age and sex-matched patients in each group. Both groups had comparable IOP before surgery (P = 0.61). The AGV group had significantly lower IOP compared to AADI group (7.05 ± 4.22 mmHg vs 17.90 ± 10.32 mmHg, P = 0.001) at 1 week. The mean postoperative IOP at 6 months was not significantly different in the two groups (13.3 ± 4.2 and 11.4 ± 6.8 mmHg respectively; P = 0.48). At 6 months, complete success rate according to antiglaucoma medication criteria was 78.94% in AADI and 47.36% in AGV groups. AGV group required 1.83 times more number of topical medications than AADI group. There was no significant difference in early (P = 0.75) and late (P = 0.71) postoperative complications in the AADI and AGV group. The complete success rate was higher in AADI group (68.42%) than AGV group (26.31%) (P = 0.034). Conclusion: In this study, AADI appears to have comparable efficacy versus AGV implant with higher complete success rate at 6 months follow-up.
机译：目的：研究与难治性青光眼患者相比，Aurolab水性引流管植入物（AADI）与艾哈迈德青光眼瓣膜（AGV）的疗效。方法：将18岁的计划青光眼引流器（GDD）随机分为两组，分别接受AGV或AADI。主要结果指标：眼内压（IOP）控制和抗青光眼药物需求;次要结局指标：最终最佳正确视力（log MAR），视野（视野指数[VFI]，平均偏差[MD]和模式标准偏差[PSD]），术后并发症和其他干预措施。如果没有抗青光眼药物/激光/其他青光眼手术或任何威胁视力的并发症，则IOP≥5–≤18 mmHg，即为完全成功。结果：每组有19名年龄和性别匹配的患者。两组术前眼压均相当（P = 0.61）。与AADI组相比，AGV组在1周时的IOP显着降低（7.05±4.22 mmHg对17.90±10.32 mmHg，P = <0.001）。两组术后6个月的平均眼压没有显着差异（分别为13.3±4.2和11.4±6.8 mmHg; P = 0.48）。在6个月时，根据抗青光眼药物治疗标准，AADI的完全成功率为78.94％，AGV组的完全成功率为47.36％。 AGV组所需的局部用药量是AADI组的1.83倍。 AADI和AGV组的术后早期并发症（P = 0.75）和晚期（P = 0.71）没有显着差异。 AADI组的完全成功率（68.42％）高于AGV组（26.31％）（P = 0.034）。结论：在这项研究中，AADI的疗效似乎与AGV植入物相当，在6个月的随访中完全成功率更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号